Statins Safe for Primary CVD Prevention in Old, Very Old: Daily Dose
Your daily dose of the clinical news you may have missed.
Mediterranean Diet Associated with Improved Cardiometabolic Health in Youth, According to First Meta-Analysis of its Kind
Adherence to Mediterranean diet-based interventions was associated with reductions in BP, triglycerides, total cholesterol, and LDL-C, as well as increases in HDL-C among children and adolescents.
Primary Care Reluctance to Treat Addiction Linked to Poor Institutional Support: New Study
Among GPs, IMs, FPs, the primary reason for reluctance to treat addiction is lack of support in the "institutional environment," followed by concerns over personal skills.
Pharmacists May be the Health Care Professionals Best Suited to Treat Hypertension
Hypertension interventions led by pharmacists and community health workers were more successful in lowering BP than those led by nurses and physicians.
Opioid Use Disorder Treatment in Primary Care: What do Patients Think?
Find key results from a new survey examining Americans' attitudes, beliefs, and knowledge about opioid use disorder treatment in primary care, here.
Long COVID Risk Declined Over the Pandemic and Vaccination was Key, But Risk Remains
Ziyad Al-Aly, MD, and colleagues link 70% of the drop in cases to vaccine availability but caution the risk for long COVID remains significant.
Disease-Tailored Preventive Intervention Reduces Alcohol Use in High-Risk Youths with Chronic Medical Conditions
Results from secondary analysis suggest future work is needed to extend the prevention intervention to address additional chronic conditions and substance use.
Semaglutide vs Tirzepatide for Weight Loss in Persons with Obesity: Daily Dose
Immunotherapy to Delay, Treat Type 1 Diabetes Wins FDA Fast Track Designation
The antigen-specific immunotherapy preserves endogenous insulin production via intralymphatic injection of recombinant GAD65 protein, according to Diamyd Medical.
FDA Declines Approval of High-Dose Naloxone Rescue Medication, OX124 for a Second Time
The FDA requested an additional human factors study and more technical data on the final commercial product.
Three Obesity-Related Comorbidities and Management Guidance for Primary Care
Get details on the relationship between obesity and mental health conditions, chronic pain, and hypertension, here.
Weight Gain in Early Adult Life Linked to Adverse Cardiac Function, Structure in Older Age
Adiposity before age 60 to 64 years, beginning as early as age 20 years, was associated with adverse cardiac structure and function not explained by current BMI.
Roche Oral Incretin Mimetic CT-966 Moves to Phase 2 Clinical Development
The oral GLP-1 RA was associated with weight loss of 7.3% in just 4 weeks and is designed with unique properties that will enhance multiple outcomes, Roche said.
Rapid Rise in Rates of Diabetes During Pregnancy in Canada Not Expected to Slow
The most concerning escalation in type 1, type 2, and gestational diabetes has been among the youngest women and girls, aged 15 to 19 years, report study authors.
Lowering Daily Sodium Intake May Reduce AF Risk in Vulnerable Adults
An analysis of 28 000 adults with vascular disease and high-risk diabetes found daily sodium intake of ≥8 g significantly increased risk for AF by 32%.
Exercise Plus Liraglutide May Preserve Bone Quality during Weight Loss: Daily Dose
Severity of SARS-CoV-2 Reinfection Similar to That of Initial Infection, According to New Findings
Researchers also found that a lower proportion of individuals were diagnosed with long COVID following reinfection than after initial infection.
Intranasal Flu Vaccine Coadministered with High-Dose Shot More Effective in Older Adults than Shot Alone
The investigational live intranasal vaccine was safe and well-tolerated when given concomitantly with Fluzone HD and the combination outperformed the latter given by itself.
GLP-1RAs Reduce Risk of Some Obesity-Related Cancers in Patients with T2D: Daily Dose
GRAIL Multicancer Early Detection Test Registrational Trials Make Good Progress, Company Says
The PATHFINDER 2 and HMS-Galleri trials are proceeding as planned with more than 175 000 participants from diverse backgrounds enrolled across both.
